Fairvalue-Calculator Fairvalue-Calculator
EN DE

Syn2bio S.A (S2B) Fair Value & Analysis

Healthcare · PL · Market cap 292M PLN

Price53.40 PLN
Fair Value5.73 PLN
Upside-89.3%
Quality87/100
Evidence: Low Range 4.30 PLN – 7.16 PLN

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Syn2bio S.A (S2B) currently trades at 53.40 PLN, while our model-based Fair Value estimate is 5.73 PLN — implying the stock looks roughly 89.3% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Syn2bio S.A., a biotechnology company, engages in the research and commercialization of Cardiac Marker, a radiopharmaceutical for diagnostic testing of heart disease in the field of myocardial perfusion. The company's flagship project is the cardiotracer project, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. Additionally, it operates The Centre for Research on New Compounds, a unit engaged in the search for new pharmaceutical compounds and their further study, registration, and market launch as a medicinal product. Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Syn2bio S.A (S2B) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 5.73 PLN versus a price of 53.40 PLN — about −89% (overvalued). Model-based estimate, not financial advice.
What is the fair value of S2B?
Our 21-model fair value for Syn2bio S.A is 5.73 PLN (as of Jun 24, 2026), built from audited fundamentals. The current price is 53.40 PLN.
What is the quality score of S2B?
Syn2bio S.A has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.